TargED Biopharmaceuticals secures €21.5 million in Series A extension funding led by BioGeneration Ventures to expedite clinical trials for its innovative thrombolytic agent, TGD001, totaling over €60 million in funding.

Information on the Target

TargED Biopharmaceuticals B.V., based in Utrecht, Netherlands, is a clinical-stage biotechnology company dedicated to creating innovative targeted treatments for thrombotic diseases. Established in 2020 as a spin-off from the University Medical Center Utrecht, TargED has successfully raised over €60 million in funding to advance its clinical pipeline. The company’s lead program, TGD001, is a first-in-class targeted thrombolytic agent designed to treat various thrombotic events by selectively degrading both von Willebrand factor (VWF) and fibrin.

The company recently announced the completion of a €21.5 million Series A extension funding round, led by Dutch life sciences venture capital firm BioGeneration Ventures (BGV). The additional funds will accelerate the clinical development of TGD001 and facilitate the launch of two Phase 1/2 clinical trials across Europe and the United States, with initial data expected in 2026. TargED aims to redefine treatment options for patients experiencing thrombosis through innovative therapeutic approaches.

Industry Overview in the Netherlands

The biotech industry in the Netherlands has gained substantial momentum in recent years, becoming one of Europe’s leading hubs for innovation in life sciences. Driven by a combination of strong academic institutions, access to capital, and supportive government polic